

## OPSYNVI - (10MG;20MG, 10MG;40MG ; Tablet)

|                              |   |                             |                     |
|------------------------------|---|-----------------------------|---------------------|
| <b>Generic Name</b>          | MACITENTAN; TADALAFIL   | <b>Innovator</b>            | Xiamen LP Pharma    |
| <b>Dosage</b>                | 10MG;20MG, 10MG;40MG ; Tablet   | <b>Branded US Sales</b>     | Less Than \$1000 mn |
| <b>Probable FTF</b>          | None  | <b>Known Para IV Filers</b> | None                |
| <b>Other ANDA developers</b> | Less Than 5   | <b>Tentative Approvals</b>  | None                |
| <b>Final Approvals</b>       | None  | <b>Generic Launches</b>     | None                |
| <b>Indication</b>            | OPSYNVI is a combination of macitentan, an endothelin receptor antagonist (ERA), and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor, indicated for chronic treatment of pulmonary arterial hypertension (PAH, WHO Group I) in adult patients of WHO functional class (FC) II-III. Individually, macitentan reduces the risk of clinical worsening events and hospitalization, and tadalafil improves exercise ability. |                             |                     |
| <b>Complexities</b>          | Yes   |                             |                     |

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.